Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Open accessAbstract
OBJECTIVE: To evaluate whether use of oral hypoglycemic agents is associated with an altered breast cancer risk in women. RESEARCH DESIGN AND METHODS: Using the U.K.-based General Practice Research Database, we conducted a nested case-control analysis among 22,621 female users of oral antidiabetes drugs with type 2 diabetes. We evaluated whether they had an altered risk of breast cancer in relation to use of various types of oral hypoglycemic agents. Case and control patients with a recorded diagnosis of type 2 diabetes were matched on age, calendar time, and general practice, and the multivariate conditional logistic regression analyses were further adjusted for use of oral antidiabetes drugs, insulin, estrogens, smoking BMI, diabetes duration, and HbA1c (A1C). RESULTS: We identified 305 case patients with a recorded incident diagnosis of breast cancer. The mean ± SD age was 67.5 ± 10.5 years at the time of the cancer diagnosis. Long-term use of ≥40 prescriptions (>5 years) of metformin, based on 17 exposed case patients and 120 exposed control patients, was associated with an adjusted odds ratio of 0.44 (95% CI 0.24–0.82) for developing breast cancer compared with no use of metformin. Neither short-term metformin use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered risk for breast cancer. CONCLUSIONS: A decreased risk of breast cancer was observed in female patients with type 2 diabetes using metformin on a long-term basis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The reduced risk of cancer and cancer mortality observed in studies of metformin users has been consistently in the range of 25% to 30%.
“The reduced risk of cancer and cancer mortality observed in these studies has been consistently in the range of 25% to 30% [135-139,145-147].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [146]
Patients with type 2 diabetes who are prescribed metformin had a lower risk of cancer compared to patients who did not take it.
“Patients with type 2 diabetes who are prescribed metformin had a lower risk of cancer compared to patients who did not take it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · see citing works
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · see citing works
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048 · see citing works
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · see citing works
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933 · see citing works
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933 · see citing works
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 2× · see citing works
“Female diabetic patients receiving neoadjuvant chemotherapy for breast cancer were reported to have a higher complete pathologic response rate if they also used metformin compared with those not using metformin (10).”
BackgroundFasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
Goodwin, P. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.42 · Cited by 867 · see citing works
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study
Goodwin, P. J., Ennis, M., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.42 · Cited by 660 · see citing works
Validity of the General Practice Research Database
Jick, S. S., Kaye, J. A., Vasilakis‐Scaramozza, C., Rodríguez, L. A. G., Ruigómez, A., Meier, C. R., Schlienger, R. G., Black, C., & Jick, H. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.686.32205 · Cited by 584 · see citing works
Self-citationMetformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502 · see citing works
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2008) · Diabetes Care · doi:10.2337/dc08-1171 · Cited by 422 · see citing works
Self-citationThe role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., PEZZINO, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 408 · see citing works
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402 · see citing works
Use of Thiazolidinediones and Fracture Risk
Meier, C., KRAENZLIN, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 353 · see citing works
Self-citationDiabetes, metabolic syndrome, and breast cancer: a review of the current evidence
Xue, F., & Michels, K. B. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.823s · Cited by 352 · see citing works
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336 · see citing works
The General Practice Research Database
Wood, L., & Martínez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 330 · see citing works
Insulin and related factors in premenopausal breast cancer risk
Giudice, M. E. D., Fantus, I. G., Ezzat, S., McKeown‐Eyssen, G., Page, D. L., & Goodwin, P. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005831013718 · Cited by 304 · see citing works
The impact of diabetes on survival following breast cancer
Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9654-0 · Cited by 176 · cited 1× · see citing works
“Furthermore, diabetes was associated with markedly increased mortality in women with breast cancer (5).”
BackgroundIs it Time to Test Metformin in Breast Cancer Clinical Trials?
Cazzaniga, M., Bonanni, B., Guerrieri‐Gonzaga, A., & DeCensi, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0871 · Cited by 133 · see citing works
Insulin, insulin-like growth factors, insulin resistance, and neoplasia
Pollak, M. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.820s · Cited by 80 · see citing works
Brauchli, Y. B., Jick, S. S., Curtin, F., & Meier, C. R. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.11.023 · Cited by 78 · see citing works
Self-citationGoodwin, P. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7132 · Cited by 77 · see citing works
Increased prevalence of prior breast cancer in women with newly diagnosed diabetes
Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9166-3 · Cited by 72 · see citing works
Kaye, J. A., Derby, L. E., Melero-Montes, M. D. M., Quinn, M., & Jick, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1493 · Cited by 45 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720 · see citing works
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992 · see citing works
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · see citing works
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · see citing works
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0103 · Cited by 520 · see citing works
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455 · see citing works
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457 · see citing works
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428 · see citing works
Metformin reduces endogenous reactive oxygen species and associated DNA damage
Algire, C., Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., & Pollak, M. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0536 · Cited by 372 · see citing works
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329 · see citing works
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320 · see citing works
Shi, W.-Y., Xiao, D., Wang, L., Dong, L.-H., Yan, Z.-X., Shen, Z.-X., Chen, S.-J., Chen, Y., & Zhao, W.-L. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.13 · Cited by 308 · see citing works
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240 · see citing works
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions
Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0615 · Cited by 202 · see citing works
Bayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176 · see citing works
<scp>NF</scp>‐κB as the mediator of metformin's effect on ageing and ageing‐related diseases
Kanigur Sultuybek, G., Soydas, T., & Yenmis, G. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13073 · Cited by 119 · see citing works
Ferroni, P., Riondino, S., Buonomo, O., Palmirotta, R., Guadagni, F., & Roselli, M. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/183928 · Cited by 87 · see citing works
Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis
Colmers, I. N., Bowker, S. L., & Johnson, J. A. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.06.003 · Cited by 81 · see citing works
Metformin: prevention of genomic instability and cancer: a review
Najafi, M., Cheki, M., Rezapoor, S., Geraily, G., Motevaseli, E., Carnovale, C., Clementi, E., & Shirazi, A. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.01.007 · Cited by 75 · see citing works
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
Mamtani, R., Pfanzelter, N., Haynes, K., Finkelman, B. S., Wang, X., Keefe, S. M., Haas, N. B., Vaughn, D. J., & Lewis, J. D. (2014) · Diabetes Care · doi:10.2337/dc13-1489 · Cited by 71 · see citing works
Vazquez-Martin, A., López-Bonetc, E., Cufí, S., Oliveras-Ferraros, C., Del Barco, S., Martin-Castillo, B., & Menendez, J. A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.04.003 · Cited by 66 · see citing works
Ariaans, G., Jalving, M., Vries, E. G. E. D., & Jong, S. D. (2017) · BMC Cancer · doi:10.1186/s12885-017-3230-8 · Cited by 51 · see citing works
Cai, H., Zhang, Y., Han, T. K., Everett, R. S., & Thakker, D. R. (2016) · International Journal of Cancer · doi:10.1002/ijc.29965 · Cited by 46 · see citing works
Metformin and cancer: licence to heal?
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499122 · Cited by 37 · see citing works
Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
Rokkas, T., & Portincasa, P. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.05.027 · Cited by 34 · see citing works
- Authors
- Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R.
- Affiliations
- Denver Health Medical Center (US)
- Boston University (US)
- University Hospital of Basel (CH)
- Corresponding author
- Meier, Christoph R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-03-18
- Volume
- 33
- Issue
- 6
- Pages
- 1304-1308
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2875444
- OpenAlex
- W2121225884
- Cited by
- 466
- References
- 26
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 12 · 2023: 10 · 2022: 28 · 2021: 26 · 2020: 23 · 2019: 29 · 2018: 18 · 2017: 32 · 2016: 30 · 2015: 33 · 2014: 39 · 2013: 50 · 2012: 47
- FWCI
- 21.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metformin, breast cancer risk, type 2 diabetes, oral antidiabetic drugs, sulfonylureas, long-term drug use, women, chemoprevention
- MeSH terms
- Aged, Breast Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Metformin, Middle Aged, Time Factors, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
